Key result
Discordant trajectories after SGLT2i initiation linked to ~327% greater risk of death or HF hospitalization.
Why the study?
To quantify the concordance and stability of symptomatic, echocardiographic, and renal trajectories following SGLT2 inhibitor initiation and determine their association with subsequent clinical events.
Does non-concordance of symptomatic, echocardiographic and renal trajectories after SGLT2i initiation predict death or heart failure hospitalization in adults with heart failure and LVEF <50%?
Cohort (n=618)
Does non-concordance of symptomatic, echocardiographic and renal trajectories after SGLT2i initiation predict death or heart failure hospitalization in adults with heart failure and LVEF <50%?
Answers are grounded in this paper and cite their sources.
Discordant symptomatic, echocardiographic, and renal trajectories are common after SGLT2i initiation in heart failure and are associated with an increased risk of death or hospitalization, primarily driven by symptomatic changes.
Objectives To quantify the concordance and stability of symptomatic, echocardiographic and renal trajectories after sodium-glucose cotransporter 2 inhibitor (SGLT2i) initiation and examine their association with subsequent events.Methods This day-210 landmark analysis included 618 adults with heart failure, baseline left ventricular ejection fraction (LVEF) <50%, and paired New York Heart Association (NYHA) class, LVEF and estimated glomerular filtration rate (eGFR) measurements on days 150–210. Domains were cross-classified rather than treated as equivalent causal components. Repeat classification was assessed by day 365. Death or heart-failure hospitalisation on days 211–365 was analysed with multivariable Cox regression; fixed-horizon Firth logistic regression and continuous, threshold, weighting and co-intervention analyses tested robustness.Results Discordant trajectories occurred in 368/618 patients (59.5%). Among 209 with repeat assessment, 181 (86.6%) retained the same classification (κ=0.74). Outcome status was complete in 576 patients, with 33 events. Non-concordance was associated with the time-to-event outcome (adjusted hazard ratio 4.27, 95% confidence interval 1.61–11.32; p = 0.004); the fixed-horizon Firth estimate was concordant (odds ratio 4.27, 95% confidence interval 1.64–11.13; p = 0.003). NYHA improvement contributed most of the prognostic signal. Adding non-concordance to a conventional baseline model increased the area under the curve from 0.752 to 0.790, but the bootstrap interval for the increment included zero.Conclusion Trajectories were frequently discordant and usually stable to day 365. Their association with events was non-causal, driven predominantly by symptomatic change and of uncertain incremental predictive value.
No takes yet. Share an insight, caveat, or question.
Jurin et al. (2026) conducted a cohort in heart failure (n=618). Discordant clinical trajectories vs. Concordant clinical trajectories was evaluated on Death or heart-failure hospitalisation on days 211–365 (HR 4.27, 95% CI 1.61-11.32, p=0.004). Discordant clinical trajectories after SGLT2 inhibitor initiation were associated with increased risk of death or heart-failure hospitalization.
Synapse has enriched 10 related papers. Consider them for comparative context: